With Delisting Fears Gone, This Stock Is Back in the Game

After months of speculation, this company silenced delisting concerns by filing its overdue Q2 report. It didn’t just meet expectations, it posted a surprise profit. With the Nasdaq threat behind it, investors are turning to the real question: Is this the start of a long-term recovery?

Every market cycle produces a select group of companies that drastically outperform the rest.

The latest screening has pinpointed the 5 Stocks Set to Double, each showing rare traits linked to early stage momentum.

These names carry the same type of indicators that have historically appeared ahead of strong rallies.

Earlier reports featured stocks that delivered +175%, +498%, and +673%.

Get the Free 5 Stocks Set to Double Report.

U.S. markets ended mixed as stronger-than-expected job gains clashed with a rise in the unemployment rate to a four-year high, raising fresh uncertainty around the labor market’s health. Investors digested the conflicting signals while awaiting key CPI data and clarity on Fed rate policy.

Ford (NYSE: F) just put a hard number on a shift that many automakers have been circling around but not admitting.

The $19.5 billion EV write-down marks a moment where ambition meets reality, and you see a company choosing clarity over narrative.

This is not Ford walking away from electric vehicles. It is Ford acknowledging that early assumptions on demand, pricing, and policy moved faster than buyers were willing to follow.

Capital Moves Back Toward What Sells

By clearing out overstated EV investments, Ford frees capital for hybrids, gas-powered models, and factory efficiency.

That reallocation matters because when you look at current sales trends, those segments are carrying margins while EV volumes stay uneven.

The reset gives Ford flexibility to build what customers are actually buying today.

It also lowers pressure on plants and supply chains that were scaled for demand that never fully arrived.

A Slower Transition With Fewer Mistakes

The write-down sends a blunt message across the industry.

The EV transition is still underway, but it rewards patience, discipline, and cost control far more than speed.

For Ford, the strategy now centers on balance rather than headlines.

And when you strip away the noise, this move positions the company to protect cash flow while keeping EV options alive for a market that is still finding its footing.

Pfizer (NYSE: PFE) is moving through a necessary transition as pandemic-driven revenue fades and competitive pressure rises across older drugs. Inside that shift, you can spot a company choosing long-term repair instead of trying to smooth the numbers.

Rather than stretching the COVID story, Pfizer is openly treating this phase as a reset. The focus now is on rebuilding growth engines that take time, patience, and scientific depth.

Where the Next Growth Engine Is Forming

Capital and research effort are being redirected toward oncology and obesity, two areas with massive long-run demand and brutal competition. In those programs, you are watching Pfizer try to replace aging blockbusters with therapies that can scale globally.

These pipelines are not quick fixes. They are designed to mature over the years, giving Pfizer a chance to reestablish leadership where medical need and pricing power still exist.

Tighter Operations, Longer Vision

Alongside R&D, Pfizer is cutting costs, simplifying manufacturing, and tightening internal execution.

That discipline matters because when launches arrive, you want the organization ready to support them at scale.

This moment signals intent. Pfizer is accepting short-term pressure to rebuild durability, scientific relevance, and competitive footing in a healthcare market that punishes complacency.

The next leg of AI growth is set to emerge from advanced data infrastructure, a segment gaining powerful momentum beneath the surface.

Leaders in this space are showing strong operational expansion, increasing government interest, and growing enterprise adoption.

These developments are quietly creating high-probability setups for early movers.

As demand accelerates, positioning inside this sector could produce significant compounding potential.

A FREE report highlights all nine opportunities poised to benefit from this surge.

Download your FREE Report Now.

Paramount (NASDAQ: PARA) has moved from speculation to action, launching a direct challenge in the race for Warner Bros.

Discovery. The decision instantly tightens the competitive field and raises the stakes for every major streaming and studio player.

A Shock That Reorders the Room

Paramount’s all-cash bid lands with speed and intent, cutting through months of cautious deal talk.

The offer reframes the situation from negotiation to confrontation, where timelines and leverage suddenly compress.

This is not a symbolic gesture meant to influence headlines.

It is a pressure move designed to force boards, regulators, and rivals to respond under a faster and less comfortable clock.

Choosing Power Over Positioning

By pursuing Warner assets, Paramount signals it wants ownership, not dependency, at the center of its future.

Within this strategy, you find a company prioritizing franchises, studios, and distribution over short-term streaming optics.

That decision reshapes how Paramount competes for talent, pricing power, and long-term relevance.

It also locks the company into a path where scale is built decisively rather than negotiated slowly.

Speed as a Strategic Weapon

The bid structure favors clarity, cash certainty, and fast execution over layered deals that drift for years.

That approach matters in a market where hesitation often destroys value before integration even begins.

Even if the bid ultimately fails, the signal still sticks.

You are looking at a Paramount that has chosen to act like an aggressor, shaping outcomes instead of waiting for consolidation to decide its future.

👉 Click here to get our closing report to your cell for free!

B. Riley Financial, Inc [RILY] $5.72 (+53.76%)

B. Riley surged after filing its delayed Q2 financials ahead of a Nasdaq deadline, easing delisting fears and showing a return to profitability.

Cementos Pacasmayo S.A.A [CPAC] $10.75 (+53.76%)

Cementos Pacasmayo climbed after Holcim agreed to acquire a controlling stake at a premium valuation tied to record EBITDA performance.

Emerald Expositions Events Inc [EEX] $4.97 (+40.40%)

Emerald advanced after announcing a strategic review following acquisition inquiries, fueling speculation of a potential buyout.

Cadrenal Therapeutics Inc [CVKD] $8.25 (-32.87%)

Cadrenal dropped after announcing a discounted registered direct offering, raising dilution concerns for existing shareholders.

Jyong Biotech Ltd [MENS] $15.40 (-31.22%)

Jyong Biotech slid as negative analyst ratings and weak technical signals reinforced bearish sentiment amid a steep downtrend.

Navan Inc [NAVN] $12.90 (-11.86%)

Navan tumbled after reporting widening quarterly losses and announcing its CFO’s departure, despite solid revenue growth.

We’re sharing a free copy of our brand-new report: 7 Best Stocks for the Next 30 Days.

For decades, our objective, mathematical stock prediction system has delivered market-beating results, identifying trades with exceptional potential.

This report uncovers the 7 highest-potential stocks from our top-rated selections — fewer than 5% of all stocks qualify.

These could be the most exciting short-term trades in your portfolio.

Act now and download your free copy and be ready for the next move.

[Get the Free Report]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.